Nonalcoholic fatty liver disease (NAFLD) is defined as hepatic steatosis without significant alcohol consumption or other known liver diseases. It includes nonalcoholic fatty liver (NAFL) characterized by hepatic fat accumulation without inflammation or fibrosis, and nonalcoholic steatohepatitis (NASH) characterized by fat accumulation with inflammation and hepatocyte injury. NAFLD is strongly associated with obesity and metabolic syndrome. Lifestyle interventions including weight loss and exercise are recommended first-line treatment, while pioglitazone and vitamin E may improve liver histology in non-diabetic adults with NASH. Liver biopsy is needed to distinguish NASH from NAFL and assess fibrosis to guide management.
NAFLD is a vast topic and recently gaining a lot of importance. Fatty liver, NASH, are other topics discussed here. sleissenger, sheila sherlock and Harrisons are used for reference
this was the first lecture which i delivered as a doctor. it was about dyslipidemia. i hope you will find information valuable to you here. please read. let me know about your ideas. comment.
NAFLD is a vast topic and recently gaining a lot of importance. Fatty liver, NASH, are other topics discussed here. sleissenger, sheila sherlock and Harrisons are used for reference
this was the first lecture which i delivered as a doctor. it was about dyslipidemia. i hope you will find information valuable to you here. please read. let me know about your ideas. comment.
By Dr. Usama Ragab, Zagazig Faculty of Medicine
PSC incidence ranges from 0.5 to 1.25 cases/100 000.
The prevalence of the disease ranges between six and 20 cases/100 000.
Men are more likely to be affected (70%).
Prevalence of PSC may be increased in first degree relatives of PSC patients
Seminar present the Upper Gastrointestinal Bleeding problems
Edited by : Dr. Inzar Yassen & Dr. Ammar L. Aldwaf
in Hawler Medical Uni. collage of medicine in 14/01/2014
Iraq - Kurdistan - Erbil
By Dr. Usama Ragab, Zagazig Faculty of Medicine
PSC incidence ranges from 0.5 to 1.25 cases/100 000.
The prevalence of the disease ranges between six and 20 cases/100 000.
Men are more likely to be affected (70%).
Prevalence of PSC may be increased in first degree relatives of PSC patients
Seminar present the Upper Gastrointestinal Bleeding problems
Edited by : Dr. Inzar Yassen & Dr. Ammar L. Aldwaf
in Hawler Medical Uni. collage of medicine in 14/01/2014
Iraq - Kurdistan - Erbil
Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. The report includes detailed competitive landscape of the global nonalcoholic steatohepatitis market and an analysis of Porter’s five forces model for the NASH market has also been included.
Nonalcoholic Steatohepatitis (NASH) also known as “silent disease” is a type of fatty liver disease, which mainly affects people with diabetes and obesity. Symptoms of NASH are found among all demographics (from children to adults); however, they are more prevalent in younger people. Corner stage of cirrhosis is a form of NASH that can be reversed with proper medication. Moreover, most of the NASH specific pharmaceutical solution are in clinical trial phase
Nonalcoholic Steatohepatitis (NASH) is a type of NAFLD (Nonalcoholic Fatty Liver Disease) which is characterized by inflammation and buildup of excess of fat in the liver. NASH is considered to be strongly associated with insulin resistance, central obesity, reduced glucose tolerance, type II diabetes mellitus (T2DM), arterial hypertension, and hypertriglyceridemia.The exact cause of the NASH has not been illuminated because generally it not same for every patient.
Emergence of noninvasive diagnostic methods for identifying patients (and stratify the NAFLD and NASH populations based on severity and risk of progression) would be a key driver, with significant impact on evolving the market for NASH therapies.
Differences in method of assessment of NASH (Ultrasound, MRI, Liver biopsy, non-invasive tests leads to profound variation in prevalence rates. We estimated that diagnosed NASH prevalence will reach 18 Million by 2027at a compound growth rate of 2.82% for seven major markets i.e. US, EU5 and Japan.
In the United States, we found that NASH Fibrosis (F0) and NASH Fibrosis-1 (F1) accounts for approximately 67% and 13% cases of total NASH respectively.
INTRODUCTION:
▶ Most common among all Liver disorders & the cause of CLD
▶ Commonest cause of asymptomatic abnormal LFTs
▶ Most common cause of End stage liver disease requiring liver transplantation
▶ Present in 75% of the individuals with Obesity and Type 2DM
▶ NAFLD exists as a spectrum from simple steatosis to cirrhosis
▶ Hepatic steatosis describes accumulation of fat >5% of liver weight
▶ Commonest cause of death in patients with NAFLD, NAFL and NASH is cardiovascular disease
NAFLD -DEFINITION:
Evidence of hepatic steatosis (Imaging/Histology)
No cause for secondary fat accumulation
(significant alcohol consumption, drugs, hereditary conditions)
Working Classification of NAFLD
NNFL(Non NASH Fatty Liver) Type 1 : Only steatosis
Type 2 : Steatosis + non specific lobular inflammation
NASH( Non alcoholic Steatohepatitis)
Type 3 : Steatosis + Inflammation +/- Fibrosis of variable levels
Type 4 : Steatosis + Inflammation + Hepatocyte ballooning + Fibrosis/Mallory Denk bodies
Nonalcoholic Fatty Liver Disease (NAFLD) Encompasses the entire spectrum of fatty liver disease in individuals without significant alcohol consumption, ranging from fatty liver to steatohepatitis and cirrhosis.
Nonalcoholic Fatty Liver (NAFL) Presence of hepatic steatosis with no evidence of hepatocellular injury in the form of ballooning of the hepatocytes or no evidence of fibrosis. The risk of progression to cirrhosis and liver failure is minimal.
Nonalcoholic steatohepatitis (NASH) Presence of hepatic steatosis and inflammation with hepatocyte injury (ballooning) with or without fibrosis. This can progress to cirrhosis, liver failure and rarely liver cancer.
NASH Cirrhosis Presence of cirrhosis with current or previous histological evidence of steatosis or
steatohepatitis
Cryptogenic Cirrhosis Presence of cirrhosis with no obvious etiology. Patients with cryptogenic cirrhosis are heavily enriched with metabolic risk factors such as obesity and metabolic syndrome.
DIAGNOSIS:
NAFLD/NASH is a diagnosis of exclusion, and liver biopsy will often be required to confirm the diagnosis, stage the disease, rule out other liver diseases, and determine the need for and urgency of aggressive therapy
DIAGNOSIS
WHEN TO SUSPECT NAFLD???
History : no symptoms ,fatigue, malaise and abdominal discomfort.
▶ The presence of any of the following, especially with a history of abnormal AST/ALT, should lead to a work-up for NAFLD/NASH:
Presence of obesity, especially morbid obesity (BMI > 35)
Diagnosis of type 2 diabetes mellitus
Diagnosis of metabolic syndrome
History of obstructive sleep apnea
Presence of insulin resistance
Chronic elevation of AST/ALT, otherwise unexplained
Detailed patient history of alcohol consumption—threshold < 20 g/day in women, < 30 g/day in men.
▶ Physical examination :
Central obesity correlates with severity of inflammation on biopsy
dorsocervical lipohypertrophy (buffalo hump) correlates with hepatocyte injury.
advanced liver disease: spider ang
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
2. DEFINITION
Nonalcoholic Fatty Liver Disease (NAFLD)
(a) there is evidence of hepatic steatosis, either by imaging or
by histology and
(b) (b) there are no causes for secondary hepatic fat
accumulation such as significant alcohol consumption, use
of steatogenic medication or hereditary disorders
Histologically further categorized into
Nonalcoholic Fatty Liver (NAFL)
Nonalcoholic Steatohepatitis (NASH)
3.
4. NONALCOHOLIC FATTY LIVER
DISEASE (NAFLD)
Most common of All liver Disorders
Most frequent cause of chronic liver disease
most common cause of End stage Liver
Disorder Needing liver transplantation.
Present in up to 75% of individuals with
obesity and type 2 Diabetes
Present in 3% of children and > 50%obese
children.
5. Nonalcoholic Fatty Liver (NAFL)
Evidence of Hepatic steatosis either by imaging or Histology
(> 5% of hepatocytes histologically) without any other Cause
for secondary Fat Accumulation with no evidence of
hepatocellular injury in the form of ballooning of the
hepatocytes or no evidence of fibrosis.
The risk of progression to cirrhosis and liver failure is minimal.
Nonalcoholic steatohepatitis (NASH)
Presence of hepatic steatosis and inflammation with hepatocyte
injury (ballooning) with or without fibrosis.
This can progress to cirrhosis, liver failure and rarely liver cancer
12. PREVALENCE OF NAFLD IN HIGH RISK
GROUPS
Population studied prevalence of NAFLD
excessive BMI and visceral obesity are
recognized risk factors
Severe obesity undergoing bariatric
surgery
90% NAFLD
5% of patients may have
unsuspected cirrhosis
An ultrasonographic study of patients
with T2DM
69% prevalence of NAFLD
Another study 127 of 204 diabetic patients
displayed fatty infiltration on ultrasound,
62% fatty infiltration and 87%
those who consented to
biopsy had histologic
confirmation of NAFLD
Individuals with dyslipidemia attending
lipid clinics
prevalence of NAFLD
estimated to be 50%.
13.
14. PATHOGENESIS AND RISK FACTORS
Insulin resistance is related to obesity and is central to the
pathogenesis of NAFLD.
In addition, oxidative stress and cytokines are important contributing
factors, together resulting in steatosis and progressive liver damage
in genetically susceptible individuals.
Key histologic components of NASH are steatosis, hepatocellular
ballooning, and lobular inflammation
19. PROGNOSIS AND COMPLICATIONS
Disease progression from NAFLD to NASH to cirrhosis/liver
failure and HCC.
Concurrence of NAFLD with hepatitis C or human
immunodeficiency virus (HIV) worsens their prognoses and
decreases their responses to therapy.
Liver biopsy may indicate the severity of disease, but only
fibrosis, and not inflammation or necrosis, has been confirmed
to predict the disease prognosis.
End-stage NASH is an often under-recognized cause of
cryptogenic cirrhosis
NASH-related (cryptogenic) cirrhosis increases the risk of
hepatocellular carcinoma (HCC).
24. Independent predictors for progression of
fibrosis:
Age > 45–50
BMI > 28–30 kg/m2
Degree of insulin resistance
Diabetes
Hypertension
The degree of fibrosis on liver biopsy (stage) is predictive of the prognosis
28. DIAGNOSIS
PATIENT HISTORY AND CLINICAL EVALUATION
Asymptomatic
vague symptoms of fatigue, malaise, and
abdominal discomfort.
Detailed patient history of alcohol—
Appropriate specialized questionnaires or scoring
systems for the evaluationof alcohol
consumption Eg.— CAGE questionnaire
29. Abdominal obesity
Enlarged liver
RUQ tenderness on palpation
Central obesity correlates with severity of inflammation
on biopsy, and dorsocervical lipohypertrophy (buffalo
hump) correlates with hepatocyte injury.
In case of progression/advanced liver disease: spider
angiomas, ascites, hepatomegaly, splenomegaly, palmar
erythema, jaundice, hepatic encephalopathy.
Physical exam
30. The presence of any of the following, especially
with a history of abnormal AST/ALT, should
lead to a work-up for NAFLD/NASH:
— Presence of obesity, especially morbid obesity (BMI > 35)
— Diagnosis of type 2 diabetes mellitus
— Diagnosis of metabolic syndrome
— History of obstructive sleep apnea
— Presence of insulin resistance
— Chronic elevation of AST/ALT, otherwise unexplained
32. ROUTINE LABORATORY FINDINGS AND
IMAGING TESTS
Elevated ALT and AST:
In 10% of NASH patients, ALT and AST may be normal,
especially with simple steatosis.
AST/ALT ratio < 1—this ratio is usually > 2 in alcoholic
hepatitis.
An abnormal ferritin level in the presence of normal
transferrin saturation should always suggest a need to
rule out NASH.
Tests to exclude: secondary causes of hepatic steatosis
33. Imaging - confirming fat accumulation in
the liver:
• The magnetic resonance imaging (MRI) test has a
quantitative value, but cannot distinguish between NASH
and ASH.
• Ultrasound is the usual screening test for fatty liver.
34. WHEN TO OBTAIN A LIVER BIOPSY
IN PATIENTS WITH NAFLD?
Liver biopsy should be considered in patients with NAFLD who are at
increased risk to have steatohepatitis and advanced fibrosis. (Strength
– 1, Evidence - B)
The presence of metabolic syndrome and the NAFLD Fibrosis Score
may be used for identifying patients who are at risk for steatohepatitis
and advanced fibrosis. (Strength – 1, Evidence - B)
Liver biopsy should be considered in patients with suspected NAFLD in
whom competing etiologies for hepatic steatosis and co-existing chronic
liver diseases cannot be excludedwithout a liver biopsy. (Strength – 1,
Evidence - B)
37. A wide variety of attempts have been made to develop
scoring systems or imaging techniques that will allow
noninvasive diagnosis of NASH and avoid the need for a
liver biopsy.
Specialized imaging modalities, including FibroScan, using
a novel “controlled attenuation parameter,” and positron
emission tomography (PET) scanning suffer from the same
limitations of limited availability, high cost, and lack of
sufficient controlled data.
NON-INVASIVE ASSESSMENT OF
STEATOHEPATITIS AND ADVANCED
FIBROSIS IN NAFLD
38. NON-INVASIVE ASSESSMENT OF
STEATOHEPATITIS AND ADVANCED
FIBROSIS IN NAFLD
The NAFLD Fibrosis Score
Enhanced Liver Fibrosis (ELF) panel
Transient Elastography
Circulating levels of cytokeratin-18 (CK18)
41. MANAGEMENT
Therapeutic rationale
Targets for therapy : insulin resistance and
oxidative stress
Goals of treatment: reduce the histologic
features and improve insulin resistance and liver
enzyme levels.
42. LIFESTYLE
INTERVENTION
Weight loss generally reduces hepatic steatosis,
achieved either by hypocaloric diet alone or in
conjunction with increased physical activity.
Loss of at least 3–5% of body weight appears
necessary to improve steatosis, but a greater
weight loss (up to 10%) may be needed to improve
necroinflammation.
Exercise alone in adults with NAFLD may reduce
hepatic steatosis but its ability to improve other
aspects of liver histology remains unknown.
43. AVOID FRUCTOSE
Fructose (+++++ in corn syrup)
Soda, canned industrial dishes
Experimental Data
Mice fed with fructose devaloped more severe inflamatory
injuries compare to High fat diet Mice
-kholi, Hepatology 2010-
Human Data
In patients with NASH fructose consumption is associated
with liver fibrosis
-Abdel malek Hepatology 2010-
44. INSULIN SENSITIZING AGENTS
METFORMIN
A recent meta analysis concluded that 6–12 months of metformin
plus lifestyle intervention did not improve aminotransferases or
liver histology, compared with lifestyle intervention alone,
independently of metformin dose or the presence of diabetes.
June 2012 AGA 1597
Metformin has no significant effect on liver histology and is not
recommended as a specific treatment for liver disease in adults
with NASH. (Strength – 1, Evidence - A)
45. INSULIN SENSITIZING AGENTS
THIAZOLIDINEDIONES
•Rosiglitazone**: improved enzymes and
steatosis, but not inflammation
•Pioglitazone:***+weight gain, but
significantly improved aminotransferases,
steatosis, ballooning, and inflammation
*Uygun, et al Aliment Pharm Ther 2004
*Nair, et al Aliment Pharm Ther 2004
**Ratziu, et al Gastroenterology 2008
***Sanyal, et al NE J Med 2010
46. PIVENS STUDY
Pioglitazone , Vitamin E, placebo
96 weeks
Adults
• with NASH
• without DM, cirrhosis, Hep C, heart failure
• limited alcohol intake over previous 5 years
Randomized trial
• Pio group: 80
• Vit E group: 84
• Placebo: 83
Sanyal et al, New England J of Medicine 2010
47. PRIMARY OUTCOME
Vitamin E vs placebo
43% improvement
vs 19%: significant
(Steatosis, lobular
inflammation,
hepatocellular
ballooning and fibrosis)
Pio vs placebo
34% improvement
vs 19%: not significant
Sanyal et al, New England J of Medicine 2010
48. SECONDARY
OUTCOME
Vitamin E vs
placebo
• Also reduction in
SGOT/SGPT
Pio vs placebo
• Reduction in SGOT/SGPT
• Reduction in steatosis,
lobular inflammation
• Improvement in IR
• Increase in weight that did
not resolve after
discontinuance of Pio
Sanyal et al, New EngJ of Med 2010
49. PIVEN
CONCLUSIONS
Vitamin E was superior to placebo in adults with NASH and
without DM
Pioglitazone may have a role in treating patients with biopsy-
proven NASH, however long term safety and efficacy has not
been established
Sanyal et al, New EnglJ of Med 2010
50. AASLD
RECOMMENDATIONS:
Pio can be used to treat certain patients with biopsy-proven
NASH who do not have DM but long term safety and efficacy
has not been established
Vitamin E 800 IU/day improves liver histology in NASH pts
• Not recommended to treat NASH in those with other chronic
liver diseases, diabetics, those with NASH cirrhosis or
cryptogenic cirrhosis, NAFLD without biopsy
51. Oxidative stress is considered to be a key mechanism of hepatocellular
injury and disease progression in subjects with NASH.
Vitamin E is an anti-oxidant and has been investigated to treat NASH
the use of vitamin E is associated with a decrease in aminotransferases
in subjects with NASH,
causes improvement in steatosis, inflammation, and ballooning and
resolution of steatohepatitis in adults with NASH
vitamin E has no effect on hepatic fibrosis.
52. Vitamin E (-tocopherol) administered at daily dose of 800 IU/day
improves liver histology in non-diabetic adults with biopsy-proven NASH
and therefore it should be considered as a first-line pharmacotherapy for
this patient population.
(Strength – 1, Quality – B)
Until further data supporting its effectiveness become available, vitamin
E is not recommended to treat NASH in diabetic patients, NAFLD without
liver biopsy, NASH cirrhosis, or cryptogenic cirrhosis. (Strength – 1,
Quality – C)
53. VITAMIN E: OTHER
CONCERNS
Meta-analysis* including 136,000 participants found
taking Vitamin E supplements > 400 IU/day had a higher
risk of all cause mortality
Vitamin E** > 400 IU/day increases risk of prostate
cancer in relatively healthy men
*Miller et al Annals of Internal
Medicine 2005
** Klein, et al, JAMA 2011
54. URSODEOXYCHOLIC ACID (UDCA),
OMEGA-3 FATTY ACIDS
UDCA : no histologic benefit
UDCA is not recommended for the treatment of NAFLD or NASH.
(Strength – 1, Quality – B)
It is premature to recommend omega-3 fatty acids for the specific
treatment of NAFLD or NASH but they may be considered as the
first line agents to treat hypertriglyceridemia in patients with
NAFLD. (Strength – 1, Quality – B)
A large multicenter study of one omega-3 fatty acid
(eicosapentanoic acid) to treat NASH is ongoing in the United
States
55. STATIN USE IN PATIENTS WITH
NAFLD AND NASH
CVD common cause of death for NAFLD and NASH
Stratify risks and treat accordingly
Several studies show NAFLD and NASH pts are not at increased
risk of liver injury over general population*
Until RCTs with histological endpoints prove their efficacy, statins
should not be used to specifically treat NASH.
(Strength – 1, Quality – B)
*Chalasani, et al. Am J Gastro 2012
56. GREACE STUDY*
Concluded statins significantly
improve liver biochemistries and CV
outcomes in pts with elevated
enzymes likely due to NASH
Athyros et al Lancet 2010
57. AASLD RECOMMENDATION ON
STATINS
“Given lack of evidence that patients with NAFLD and NASH are at
increased risk for serious drug-induced liver injury from statins,
they can be used to treat dyslipidemia in patients with NAFLD and
NASH.”
58. BARIATRIC SURGERY
No RCTs
Cochrane review 2010: lack of RCTs prevents
definitive assessment of risks/benefits
Prospective study*
• 381 adults with severe obesity, fibrosis score<3
• Clinical, metabolic, liver biopsy comparisons at 1 year
and 5 years
• Significant improvement in steatosis, ballooning,
resolution of probable/definite NASH at 1 and 5 years
• Small but significant increase of fibrosis score at 5
years (96% had improvement)
*Mathurin et al Gastroenterology 2009
59. AASLD RECOMMENDATION
ON BARIATRIC SURGERY
Premature to consider foregut surgery as an option to
specifically treat NASH
Foregut surgery is not contra-indicated in otherwise eligible
pts with NASH or NAFLD WITHOUT cirrhosis
For those with cirrhosis: type, safety and efficacy of foregut
surgery is not established
61. MISCELLANEOUS RECOMMENDATIONS
PERTINENT TO CLINICAL PRACTICE
Patients with NASH cirrhosis should be screened for
gastroesophageal varices according to the AASLD/ACG practice
guidelines. (Strength – 1, Quality – B)
Patients with NASH cirrhosis should be considered for HCC
screening according to the AASLD/ACG practice guidelines.
(Strength – 1, Quality – B)
Current evidence does not support routinely repeating a liver
biopsy in patients with NAFL or NASH. (Strength – 2, Quality –
C)
62. SUMMARY
Metabolic Syndrome and NAFLD has reached epidemic
proportions
NFLD can lead to Cirrhosis and HCC
Patients with NFLD have lower overall survival
The diagnosis should be sought in all patients who present with
risk factors for NASH. Not all patients with risk factors will have
NAFLD or NASH, and not all patients with NASH will have
standard risk factors.
NFLD is a cofactor of liver progression
Lifestyle diet and Exercise still represents crucial therapeutic
measures
More trials are needed to validate efficient drugs
63. REFERENCES
World Gastroenterology Organisation Global Guidelines
Nonalcoholic Fatty Liver Disease and Nonalcoholic
Steatohepatitis June 2012
The Diagnosis and Management of Non-alcoholic Fatty Liver
Disease: Practice Guideline by the American
Gastroenterological Association, American Association for the
Study of Liver Diseases, and American College of
Gastroenterology June 2012
AASLD PRACTICE GUIDELINE
The Diagnosis and Management of Non-Alcoholic Fatty Liver
Disease: Practice Guideline by the American Association for the
Study of Liver Diseases, American College of Gastroenterology, and
the American Gastroenterological Association 2012